Modulari-T

Executive Summary

Modulari-T is a Canadian biotechnology company pioneering modular gene-therapy platforms based on proprietary AAV vector technology. Founded in 2020 and headquartered in Toronto, the company focuses on precise delivery of therapeutic genes to address rare diseases and oncology. By engineering customizable AAV capsids and expression cassettes, Modulari-T aims to overcome limitations of conventional gene therapies, such as immunogenicity and tissue specificity. The platform is designed to be rapidly adapted across multiple indications, accelerating preclinical and clinical development. Currently in preclinical stage, the company has built a team of 50–200 employees and is advancing its lead programs toward IND-enabling studies.

Upcoming Catalysts (preview)

• Q4 2026Lead Program Preclinical Data Readout70% success
• Q2 2027IND Filing for First Therapeutic Candidate55% success
• Q1 2027Strategic Partnership or Licensing Deal60% success